Melanocytic Lesions and Melanoma Pathology

Molecular and Cellular Mechanisms of Malignant Transformation

• BRAF and NRAS Mutations in Melanomagenesis: Activating mutations in BRAF (V600E most common, ~50% of cutaneous melanomas) and NRAS (~20-30% of melanomas) drive constitutive activation of the MAPK/ERK signaling pathway, promoting uncontrolled proliferation and survival. BRAF mutations predominantly occur in melanomas with chronic sun damage or arising in intermittently exposed sites, while NRAS mutations show different epidemiologic associations. These mutations promote transition from benign nevi (which often harbor the same BRAF mutations) to invasive melanoma through acquisition of additional genetic alterations. KIT mutations (3-5% of melanomas) occur predominantly in acral and mucosal melanomas and confer differential treatment sensitivity to tyrosine kinase inhibitors.

• TP53 and CDKN2A/p16 Loss: Loss of function of TP53 through mutation or deletion eliminates critical checkpoint control of cell cycle progression and apoptosis, allowing damaged cells to proceed through the cell cycle. CDKN2A/p16 inactivation through methylation, deletion, or mutation abrogates G1/S checkpoint control by reducing CDK4/6 inhibition, facilitating progression from benign to dysplastic nevi and eventually to melanoma. Familial melanoma syndromes frequently feature germline CDKN2A mutations, conferring 70-80% lifetime risk of melanoma development. These alterations typically represent later events in melanomagenesis, distinguishing invasive melanoma from benign proliferations that may harbor BRAF mutations alone.

• PTEN Loss and PI3K/AKT Pathway Activation: Inactivation of PTEN, a critical phosphatase opposing PI3K signaling, occurs in 30-50% of melanomas and promotes survival signaling through AKT activation independent of growth factor stimulation. PTEN loss frequently co-occurs with BRAF or NRAS mutations, synergistically enhancing transformation potential. This mechanism is particularly important in understanding resistance to BRAF inhibitors, as PTEN-deficient melanomas demonstrate enhanced survival signaling through alternative pathways. The combined loss of PTEN and activation of BRAF dramatically accelerates melanomagenesis in mouse models, demonstrating the requirement for multiple genetic "hits."

• Telomerase Reactivation and Genomic Instability: Most melanomas reactivate telomerase (hTERT) through TERT promoter mutations (~70% of melanomas) or ATRX/DAXX alterations, bypassing senescence checkpoints and enabling unlimited proliferative potential. Reactivation of telomerase typically occurs at the transition from dysplastic nevus to melanoma, representing a critical checkpoint in malignant transformation. Melanomas also demonstrate high mutational burden with 1,000-10,000 somatic mutations, reflecting cumulative effects of UV-induced DNA damage and impaired mismatch repair mechanisms. This mutational load directly correlates with immunogenicity and responsiveness to checkpoint inhibitor therapy.

• Epithelial-Mesenchymal Transition (EMT) and Migration: Progression from radial growth phase (RGP) to vertical growth phase (VGP) involves activation of EMT programs, with loss of E-cadherin expression and upregulation of N-cadherin, vimentin, and slug transcription factors. These molecular changes facilitate transition from intraepidermal and superficial dermal infiltration to deeper vertical invasion and vascular invasion. Downregulation of adhesion molecules and upregulation of matrix metalloproteinases (MMPs) enable invasion through dermal collagen and access to vasculature. Loss of contact inhibition coupled with EMT activation distinguishes invasive melanomas from benign nevi, which maintain cohesive architecture and E-cadherin expression.

Environmental and Exogenous Factors

• Ultraviolet (UV) Radiation Exposure: UV radiation (UVA 320-400 nm and UVB 280-320 nm) represents the most significant environmental risk factor for melanoma development, with both intermittent intense sun exposure and chronic cumulative exposure implicated. UVB induces direct DNA damage through thymine dimer formation and 6-4 photoproducts, while UVA penetrates deeper into dermis and generates reactive oxygen species. Individuals with history of severe blistering sunburns, particularly in childhood, demonstrate 3-5 fold increased melanoma risk. The "intermittent exposure hypothesis" suggests that vacational, intense sun exposure in childhood is more carcinogenic than continuous occupational exposure. Artificial UV exposure through tanning beds increases risk by 15-75% depending on age of initiation and intensity/duration of use.

• Phenotypic and Genetic Susceptibility Factors: Fair skin phototype (Fitzpatrick types I-II), red or blonde hair, and inability to tan significantly increase melanoma risk due to lower melanin production and impaired UV protection. MC1R gene variants encoding melanocortin-1 receptor account for red hair phenotype and independently increase melanoma risk 2-3 fold regardless of sun exposure. Presence of atypical (dysplastic) nevi indicates increased risk for both melanoma development (increased surveillance) and poor prognosis if melanoma develops. Familial atypical multiple mole and melanoma (FAMMM) syndrome associated with germline CDKN2A mutations confers 50-80% lifetime melanoma risk and often presents with early-onset, multiple melanomas.

• Number and Type of Nevi: Presence of >50 common nevi or >5 atypical nevi significantly increases melanoma risk through both increased cell population at risk and field effect of UV-induced damage. Large congenital nevi (>20 cm) carry lifetime melanoma risk of 5-10%, with transformation typically occurring in deeper dermal and subcutaneous components during adulthood. Multiple atypical nevi in setting of family history of melanoma (FAMMM syndrome) elevates risk 100-fold compared to general population.

Host and Medical Factors

• Immunosuppression: Solid organ transplant recipients receiving chronic immunosuppressive therapy demonstrate 20-40 fold increased melanoma risk due to impaired T-cell–mediated immune surveillance of transformed melanocytes. HIV/AIDS patients with CD4+ counts <50 cells/μL show increased melanoma incidence and more aggressive disease behavior. Patients treated with checkpoint inhibitor therapy for non-melanoma malignancies paradoxically experience increased melanoma incidence due to autoinhibition of anti-tumor immunity.

• Prior Melanoma History: Patients with history of melanoma carry 5-10% risk of developing second primary melanoma, reflecting both genetic predisposition and field effect of UV damage across entire integument. Stage III-IV melanoma confers highest risk for recurrence and metastatic disease progression, with 5-year survival rates of 40-50% for stage III and <10% for stage IV.

• Age and Sex: Melanoma incidence increases with age, with peak incidence in 6th-7th decades, though can occur at any age including childhood. Males demonstrate higher incidence and worse prognosis than females, attributable to both increased sun exposure and potential biological differences in tumor behavior.

Early Detection: ABCDE and EFGH Criteria

• Asymmetry: Benign nevi typically demonstrate bilateral symmetry, while melanomas show asymmetric morphology with unequal halves. This reflects the non-uniform, infiltrative growth pattern of melanoma. Asymmetry appears as uneven distribution of pigmentation and irregular borders within the lesion.

• Border Irregularity: Melanomas demonstrate irregular, notched, or scalloped borders, while common nevi have smooth, well-demarcated edges. Irregular borders result from heterogeneous growth rates and non-uniform invasion of melanoma cells into surrounding dermis. The transition between lesion and surrounding skin appears fuzzy or indistinct rather than sharply demarcated.

• Color Variation: Presence of multiple colors (black, brown, red, blue, white, gray) within single lesion is highly suggestive of melanoma, reflecting heterogeneous pigmentation patterns and varying depths of melanin deposition. Melanomas >5 mm are significantly more likely to have color variation than smaller lesions. Blue or steel-blue coloration indicates deeper dermal/subcutaneous involvement (Tyndall effect). White or gray areas suggest regression or loss of melanocytes.

• Diameter: Lesions >6 mm in diameter warrant heightened suspicion for melanoma, as >90% of melanomas exceed this threshold. However, early melanomas may be smaller, and size alone is insufficient for diagnosis. Melanomas demonstrate dynamic growth over weeks to months, while benign nevi remain relatively static.

• Evolution: Recent change in size, shape, color, or symptoms (itching, bleeding) in existing lesion strongly suggests melanoma. Rapid growth over 1-3 months is particularly concerning, while benign nevi remain morphologically stable over years.

• EFG Criteria (Elevation, Firmness, Growing): Elevation of lesion above skin surface, firm or raised consistency, and documented growth increase melanoma suspicion.

Symptomatology and Associated Findings

• Pruritus and Bleeding: Itching or burning sensation in lesion, particularly if new symptom, is reported in 20-30% of melanomas and reflects inflammatory infiltrate and possible neural involvement. Spontaneous or easy bleeding/oozing indicates superficial ulceration and vascular involvement. These symptoms are uncommon in benign nevi and warrant investigation.

• Nodular and Ulcerated Presentation: Nodular melanomas present as firm, raised papules or nodules, often darkly pigmented, with rapid growth over weeks. Ulcerated melanomas demonstrate erosion through epidermis with loss of surface epithelium, indicating high-grade lesion with poor prognosis. Ulceration implies deep vertical growth and represents AJCC stage modifier.

• Acral Melanomas: Melanomas on palms, soles, or nail apparatus represent 2-15% of melanomas depending on race and ethnicity. These lesions often present at advanced stage due to delayed recognition and lack of public awareness. Subungual melanoma presents as pigmented band within nail (>3 mm width, irregular borders, proximal involvement of nail fold—"Hutchinson's sign") and frequently extends to nail matrix.

• Mucosal Melanomas: Melanomas of oral cavity, nasopharynx, esophagus, or anogenital region represent 1-3% of melanomas but carry worse prognosis due to late presentation. Present as pigmented or amelanotic masses with ulceration, bleeding, or obstructive symptoms depending on location.

• Lentigo Maligna Melanoma: Presents as large (>3 cm), irregularly shaped macule with variegated pigmentation on chronically sun-exposed face, ears, or neck in elderly patients. Often has long radial growth phase lasting years before vertical invasion. Represents ~5-10% of melanomas but has better prognosis than nodular type due to prolonged horizontal growth.

• Superficial Spreading Melanoma: Most common type (70% of melanomas), presents as irregularly pigmented plaque with varied colors and irregular borders on intermittently exposed sites (back, legs). Demonstrates intermediate prognosis between lentigo maligna and nodular subtypes.

• Amelanotic Melanoma: 5-10% of melanomas lack pigmentation, presenting as pink, red, or flesh-colored nodules or papules, often misdiagnosed as benign lesions or non-melanoma skin cancer. High mortality due to delayed diagnosis, as amelanotic lesions lack warning color variation of pigmented melanomas.

Systemic and Metastatic Manifestations

• Regional Lymphadenopathy: Enlarged lymph nodes in drainage basin of primary melanoma indicate stage III disease with nodal metastases, presenting as firm, non-tender nodes. Sentinel lymph node biopsy identifies microscopic nodal involvement in clinically node-negative patients.

• Distant Metastases: Stage IV disease presents with metastatic involvement of lungs (most common), brain, liver, bone, and gastrointestinal tract. Symptoms include cough, dyspnea, neurological deficits, abdominal pain, or bone pain depending on metastatic sites. In-transit metastases appear as nodules between primary lesion and regional lymph nodes, indicating dermal lymphatic involvement.

• Constitutional Symptoms: Fever, weight loss, and malaise may accompany advanced stage III-IV disease, reflecting systemic inflammatory response to tumor burden.

Histopathological Examination (Gold Standard)

• Nevus vs Melanoma: Diagnostic Features

• Intraepidermal/In Situ Changes: Melanoma in situ demonstrates full-thickness replacement of epidermis with atypical melanocytes showing nuclear enlargement (4-5x keratinocyte nuclear size), irregular nuclear membranes, coarse chromatin, and prominent nucleoli. Pagetoid spread (upward migration of atypical melanocytes above basal layer into upper epidermis and stratum corneum) represents definitive sign of malignancy and is absent in benign nevi. Asymmetric extension of intraepidermal melanocytes beyond dermal component indicates malignant transformation. Junctional activity (melanocytes at dermal-epidermal junction) may be present but must be evaluated with context of other features.

• Dermal Invasion Patterns: Radial Growth Phase (RGP) demonstrates infiltration of dermal melanocytes with asymmetric, haphazard spread in horizontal direction with minimal vertical invasion. RGP melanomas have low metastatic potential. Vertical Growth Phase (VGP) characterized by presence of expansile nodule of melanoma cells in dermis showing uniform population with increased mitotic activity and loss of maturation (cellularity does not decrease with depth). VGP correlates with ability to metastasize and is essential for stage III/IV disease. Breslow thickness measured from granular layer (or surface if ulcerated) to deepest melanoma cell represents single most important prognostic factor.

• Cytomorphological Features of Malignant Melanocytes: Melanoma cells demonstrate enlarged nuclei (4-5x normal melanocyte size) with irregular nuclear membranes, irregular clumped chromatin, and prominent red nucleoli (using H&E staining). Cytoplasm is abundant with variable melanin content (amelanotic cells lack pigment), imparting pale appearance. Nuclear pleomorphism (variation in nuclear size and shape) and hyperchromatic nuclei (increased staining with hematoxylin) are characteristic. Mitotic figures are increased in frequency and may be atypical (tripolar, multipolar), indicating high proliferative activity. Apoptotic bodies may be present, reflecting immune destruction and tumor cell death.

• Inflammatory Infiltrate: Melanomas typically demonstrate prominent lymphocytic infiltrate composed primarily of CD8+ T cells, distinguishing them from benign nevi. This infiltrate may be brisk (associated with improved prognosis) or sparse (worse prognosis). Tumor-infiltrating lymphocytes (TILs) density correlates with immunogenicity and response to checkpoint inhibitor therapy. Presence of plasma cells, eosinophils, and macrophages indicates Th1-type immune response.

• Specialized Diagnostic Stains and Immunohistochemistry: S-100 protein marks all melanomas (100% sensitive but

Step 1 — Establish diagnosis and depth (before anything else)

• Excisional biopsy: NCCN and the American Academy of Dermatology recommend narrow-margin (1–3 mm) full-thickness excisional biopsy to the subcutis. A deep shave or partial punch that transects the base destroys Breslow thickness, the variable that drives every subsequent decision.
• Staging workup: AJCC 8th-edition staging is pathologic; imaging is reserved for node-positive or symptomatic disease rather than thin, clinically localized lesions.

Definitive local therapy

• Wide local excision: margin is dictated by Breslow thickness — roughly 0.5–1 cm for melanoma in situ, 1 cm for thin invasive lesions, and 2 cm for thick lesions, per NCCN.
• Sentinel lymph node biopsy: offered for intermediate-thickness melanoma and discussed for thin melanoma with adverse features (ulceration, greater depth). It is a staging/prognostic tool; NCCN no longer recommends routine completion lymph node dissection for a positive sentinel node, favoring nodal ultrasound surveillance.

Systemic therapy — adjuvant and metastatic

• Anti–PD-1 checkpoint inhibitors (pembrolizumab, nivolumab): backbone of adjuvant therapy for resected high-risk disease and of first-line metastatic therapy; melanoma's high UV-driven mutational burden makes it unusually immunogenic.
• Combination immunotherapy: anti–CTLA-4 plus anti–PD-1 (ipilimumab + nivolumab) or anti–LAG-3 plus anti–PD-1 (relatlimab + nivolumab) for higher-risk metastatic disease, including brain metastases.
• BRAF + MEK inhibitors (dabrafenib + trametinib; encorafenib + binimetinib): only for tumors with a confirmed BRAF V600 mutation; dual blockade prevents MAPK reactivation.
• KIT inhibition (imatinib) is an option in KIT-mutant acral/mucosal melanoma. Intralesional oncolytic therapy (talimogene laherparepvec) is used for unresectable in-transit disease.

Contraindicated / avoid

• BRAF inhibitor monotherapy in BRAF wild-type tumors: paradoxically activates CRAF/MAPK signaling and can accelerate RAS-driven growth — always test before treating, and always pair with a MEK inhibitor.
• Checkpoint inhibitors in active severe autoimmune disease or transplant recipients require careful risk–benefit weighing given rejection and flare risk.

Disease-related

• In-transit and satellite metastases: tumor emboli lodged in dermal lymphatics between the primary site and the nodal basin; signaled by new pigmented or amelanotic nodules along the lymphatic drainage path. Upstages to stage III.
• Brain metastasis: melanoma is one of the classically hemorrhagic brain metastases (with renal cell, choriocarcinoma, thyroid). New headache, seizure, or focal deficit warrants urgent neuroimaging — herniation from intratumoral hemorrhage is an emergency.
• Malignant spinal cord compression: back pain with myelopathic signs; emergency requiring immediate MRI and corticosteroids.
• Widespread visceral disease: lung, liver, bone, and uniquely the small bowel — melanoma is a leading cause of metastatic small-bowel obstruction and intussusception in adults.
• Second primary melanoma: field UV damage plus germline risk; mandates lifelong total-body skin surveillance.

Treatment-related — immune checkpoint inhibitors (immune-related adverse events)

• Colitis: loss of peripheral tolerance to gut mucosa; watery/bloody diarrhea. Perforation and toxic megacolon are emergencies. Per ASCO/NCCN irAE guidance, high-dose corticosteroids first, infliximab or vedolizumab if steroid-refractory.
• Hypophysitis and primary adrenal insufficiency: fatigue, hyponatremia, hypotension; adrenal crisis is an emergency — give stress-dose glucocorticoids before confirmatory testing.
• Myocarditis: rare but fulminant, with troponin elevation and conduction block; emergency, highest risk with combination CTLA-4/PD-1 blockade.
• Pneumonitis, hepatitis, thyroiditis, and autoimmune type 1 diabetes (may present as DKA — emergency).
• Vitiligo-like depigmentation: shared melanocyte antigens; paradoxically correlates with treatment response.

Treatment-related — targeted and surgical

• Cutaneous squamous cell carcinoma/keratoacanthoma with BRAF inhibitor monotherapy via paradoxical MAPK activation; mitigated by adding a MEK inhibitor.
• Pyrexia (dabrafenib/trametinib), reduced LVEF and serous retinopathy (MEK inhibitors), QT prolongation and photosensitivity (vemurafenib).
• Chronic lymphedema, seroma, and nerve injury after complete lymph node dissection — a major reason dissection is no longer routine.

• Breslow thickness is the single most important prognostic factor — measured in millimeters from the granular layer to the deepest tumor cell. Clark level is the classic distractor: it was dropped from AJCC 8th-edition staging and does not drive management.
• Single best next step for a suspicious pigmented lesion: narrow-margin excisional biopsy through the subcutis. Never a transecting shave and never a partial sampling of a large lesion — you lose depth. Do not "observe and recheck in 6 months."
• Pagetoid spread (atypical melanocytes scattered upward through the epidermis, buckshot scatter) plus loss of maturation with depth are the two histologic findings that separate melanoma from a benign nevus, which shows orderly maturation and no pagetoid ascent.
• BRAF V600E in roughly half of cutaneous melanomas — test before systemic therapy. BRAF inhibitors are given with a MEK inhibitor and never in BRAF wild-type tumors (paradoxical MAPK activation). KIT mutations cluster in acral and mucosal melanoma.
• Immunohistochemistry: S-100 and SOX10 are the sensitive markers (SOX10 nuclear, useful in spindle/desmoplastic cases); HMB-45 and Melan-A/MART-1 are more specific. An amelanotic spindle-cell tumor that is keratin-negative and S-100–positive is melanoma until proven otherwise — melanoma is the great mimicker.
• Nodular melanoma lacks a meaningful radial growth phase, entering vertical growth early; that is why it presents thick despite a small diameter and can fail the ABCDE "D" criterion.
• Acral lentiginous melanoma is not more common in darkly pigmented individuals in absolute terms — it is simply the proportionally predominant subtype. Hutchinson sign (pigment on the proximal nail fold) points to subungual melanoma, not a benign band.
• Melanoma brain metastases bleed; new neurologic symptoms in a melanoma patient demand urgent imaging, and new diarrhea or fatigue on a checkpoint inhibitor means colitis or hypophysitis, not gastroenteritis.